Australian Cancer Research Foundation (ACRF) Drug Discovery Centre for Childhood Cancer, Children's Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Randwick, New South Wales 2031, Australia.
Personalised Medicine Program, Children's Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Randwick, New South Wales 2031, Australia.
Nat Rev Cancer. 2016 Aug;16(8):508-24. doi: 10.1038/nrc.2016.55. Epub 2016 Jun 24.
Telomerase activity is responsible for the maintenance of chromosome end structures (telomeres) and cancer cell immortality in most human malignancies, making telomerase an attractive therapeutic target. The rationale for targeting components of the telomerase holoenzyme has been strengthened by accumulating evidence indicating that these molecules have extra-telomeric functions in tumour cell survival and proliferation. This Review discusses current knowledge of the biogenesis, structure and multiple functions of telomerase-associated molecules intertwined with recent advances in drug discovery approaches. We also describe the fertile ground available for the pursuit of next-generation small-molecule inhibitors of telomerase.
端粒酶活性负责维持大多数人类恶性肿瘤中的染色体末端结构(端粒)和癌细胞的永生性,使其成为有吸引力的治疗靶点。越来越多的证据表明,这些分子在肿瘤细胞存活和增殖中具有端粒外功能,这为靶向端粒酶全酶成分提供了依据。本综述讨论了端粒酶相关分子的生物发生、结构和多种功能的最新知识,并结合药物发现方法的最新进展进行了讨论。我们还描述了追求下一代端粒酶小分子抑制剂的有利条件。